Companies · Biotechnology

Leversense, Llc

Newtown Square · Biotechnology

Diligence memoA one-page analyst read on Leversense, Llc — recommendation, valuation, rhythm, risks.
$659K
Total raised · real
2
Rounds
1.5×
Latest step-up
Top 88%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Sun Nov 21 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Leversense, Llc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
Dormant
  • Last raise 15.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Leversense, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.0 yr record
Peak capital year was 2010 with $399K across 1 filings.
Market position
ahead of 13% of Biotechnology peers
Capital scale is ahead of 13% of Biotechnology peers; modeled value is above 30% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2010: $399K across 1 filings.
  • Largest single filing was $399K on 2010-11-21.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Leversense, Llc is one of 4291 Biotechnology companies tracked from Newtown Square. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2009-07-01 Raised $260K (real) Modeled valuation $14M (est)$260K$14MPre-Seed2009Pre-Seed · 2010-11-21 Raised $399K (real) Modeled valuation $22M (est)$399K$22MPre-Seed2010+$399KCumulative $659K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$260K · 2009
Pre-Seed extension$399K · 2010

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$22.0M
Base estimate est.
$213K
Conservative case
$249.8M
Upside case
$2.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $14.4M · 2009-07-012009Pre-Seed · modeled $22.0M · 2010-11-212010
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
15.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$474K/yr
Capital velocity
17.0 yr
On record since
2009
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$659K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.0× of median
This company$399K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$22.0M
Sector median$64.2M

Raised more than 13% of sector peers (real $). Modeled value above 30% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #64 of 132.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Iquum Inc · Pre-Seed Raised $1.0M · modeled $55.2M (est)Olive Medical Corp · Pre-Seed Raised $2.6M · modeled $55.2M (est)Hygeia Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Act Biotech Inc · Pre-Seed Raised $2.5M · modeled $55.2M (est)Microarrays, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Koronis Pharma, Inc. · Pre-Seed Raised $1.3M · modeled $55.2M (est)Ikonopedia, LLC · Pre-Seed Raised $2.8M · modeled $55.2M (est)INTICA Biomedical, Inc. · Pre-Seed Raised $1.6M · modeled $54.9M (est)LightStat, LLC · Pre-Seed Raised $970K · modeled $53.6M (est)Cyto Wave Technologies Inc. · Pre-Seed Raised $965K · modeled $53.3M (est)Curis Inc · Pre-Seed Raised $964K · modeled $53.2M (est)Real Imaging, Ltd. · Pre-Seed Raised $930K · modeled $51.3M (est)Leversense, Llc (this company) Raised $659K · modeled $22.0M (est)Leversense, Llc
CompanyStageRaised · realValue · estvs peer med.
Iquum IncPre-Seed$1.0M$55.2M2.82×
Olive Medical CorpPre-Seed$2.6M$55.2M2.82×
Hygeia Therapeutics, Inc.Pre-Seed$1.0M$55.2M2.82×
Act Biotech IncPre-Seed$2.5M$55.2M2.82×
Microarrays, Inc.Pre-Seed$1.0M$55.2M2.82×
Koronis Pharma, Inc.Pre-Seed$1.3M$55.2M2.82×
Ikonopedia, LLCPre-Seed$2.8M$55.2M2.82×
INTICA Biomedical, Inc.Pre-Seed$1.6M$54.9M2.81×
LightStat, LLCPre-Seed$970K$53.6M2.74×
Cyto Wave Technologies Inc.Pre-Seed$965K$53.3M2.72×
Curis IncPre-Seed$964K$53.2M2.72×
Real Imaging, Ltd.Pre-Seed$930K$51.3M2.62×
Leversense, Llc this companyPre-Seed$659K$22.0M1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$260K2009-07-01$1.4M$14.4M90%
Pre-Seed$399K2010-11-21$2.2M$22.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$260K2009-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$399K2010-11-21
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
Intelligence
2012 ~Q2
Modeled next raise · ~17mo cadence
$612K
Modeled next size est.range $399K$980K
1.5×
Last step-up
$474K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Peter Nagy2009-07
Registry & provenance

Leversense, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1468289
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
UberSeq, Inc.BiotechnologyPre-Seed$675K$16.6Msame sector · same stage
xMD Diagnostics, Inc.BiotechnologyPre-Seed$675K$27.6Msame sector · same stage
Antidote Therapeutics, Inc.BiotechnologyPre-Seed$632K$23.9Msame sector · same stage
MK Stem Cell Inc.BiotechnologyPre-Seed$700K$22.1Msame sector · same stage
Implicit Bioscience LtdBiotechnologyPre-Seed$702K$20.3Msame sector · same stage
Nexsis Biosciences LLCBiotechnologyPre-Seed$725K$16.0Msame sector · same stage
Vitanova Biomedical, Inc.BiotechnologyPre-Seed$745K$17.9Msame sector · same stage
Heart of Gold Laboratories, LLCBiotechnologyPre-Seed$750K$23.0Msame sector · same stage
Frequently asked
How much funding has Leversense, Llc raised?
Leversense, Llc has raised approximately $659K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Leversense, Llc's estimated valuation?
Provath's modeled valuation for Leversense, Llc is approximately $22.0M (modeled range $213K–$249.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Leversense, Llc at?
Leversense, Llc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Sun Nov 21.
What does Leversense, Llc do and where is it based?
Leversense, Llc operates in the Biotechnology sector, based in Newtown Square.
Explore related

See where Leversense, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Leversense, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.